|
CN103030617A
(zh)
*
|
2004-03-16 |
2013-04-10 |
贝林格尔.英格海姆国际有限公司 |
吡喃葡萄糖基取代的苯基衍生物、含该化合物的药物、其用途及其制造方法
|
|
DE602005009745D1
(de)
|
2004-12-16 |
2008-10-23 |
Boehringer Ingelheim Pharma |
Glucopyranosyl-substituierte benzen-derivate, medikamente mit solchen verbindungen, ihre verwendung und herstellungsverfahren dafür
|
|
JP5264183B2
(ja)
|
2005-02-23 |
2013-08-14 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
グルコピラノシル置換（（ヘテロ）アリールエチニル−ベンジル）−ベンゼン誘導体及びナトリウム依存性グルコース共輸送体２（ｓｇｌｔ２）インヒビターとしてのそれらの使用
|
|
ATE453656T1
(de)
|
2005-04-15 |
2010-01-15 |
Boehringer Ingelheim Int |
Glucopyranosyl-substituierte (heteroaryloxy- benzyl)-benzen-derivate als sglt-inhibitoren
|
|
US7723309B2
(en)
|
2005-05-03 |
2010-05-25 |
Boehringer Ingelheim International Gmbh |
Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((R)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
|
|
UA91546C2
(uk)
*
|
2005-05-03 |
2010-08-10 |
Бьорінгер Інгельхайм Інтернаціональ Гмбх |
КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ
|
|
US7772191B2
(en)
|
2005-05-10 |
2010-08-10 |
Boehringer Ingelheim International Gmbh |
Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
|
|
TW200726755A
(en)
*
|
2005-07-07 |
2007-07-16 |
Astellas Pharma Inc |
A crystalline choline salt of an azulene derivative
|
|
AR054871A1
(es)
|
2005-07-27 |
2007-07-25 |
Boehringer Ingelheim Int |
Derivados de (hetero)cicloalquiletinil-bencil)-benceno sustituidos con glucopiranosilo, medicamentos que contienen dichos compuestos, sus uso y proceso para su fabricacion
|
|
WO2007025943A2
(en)
|
2005-08-30 |
2007-03-08 |
Boehringer Ingelheim International Gmbh |
Glucopyranosyl-substituted benzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
|
|
AU2006289093A1
(en)
|
2005-09-08 |
2007-03-15 |
Boehringer Ingelheim International Gmbh |
Crystalline forms of 1-chloro-4-(beta-D-glucopyranos-1-yl)-2-(4-ethynyl-benzyl)-benzene, methods for its preparation and the use thereof for preparing medicaments
|
|
AR056195A1
(es)
|
2005-09-15 |
2007-09-26 |
Boehringer Ingelheim Int |
Procedimientos para preparar derivados de (etinil-bencil)-benceno sustituidos de glucopiranosilo y compuestos intermedios de los mismos
|
|
AR059489A1
(es)
|
2006-02-15 |
2008-04-09 |
Boehringer Ingelheim Vetmed |
Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
|
|
PE20080697A1
(es)
|
2006-05-03 |
2008-08-05 |
Boehringer Ingelheim Int |
Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
|
|
US7803778B2
(en)
*
|
2006-05-23 |
2010-09-28 |
Theracos, Inc. |
Glucose transport inhibitors and methods of use
|
|
WO2008020011A1
(en)
|
2006-08-15 |
2008-02-21 |
Boehringer Ingelheim International Gmbh |
Glucopyranosyl-substituted cyclopropylbenzene derivatives, pharmaceutical compositions containing such compounds, their use as sglt inhibitors and process for their manufacture
|
|
WO2008034859A1
(en)
*
|
2006-09-21 |
2008-03-27 |
Boehringer Ingelheim International Gmbh |
Glucopyranosyl-substituted difluorobenzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
|
|
TWI499414B
(zh)
|
2006-09-29 |
2015-09-11 |
Lexicon Pharmaceuticals Inc |
鈉與葡萄糖第２型共同運輸體（ｃｏ-ｔｒａｎｓｐｏｒｔｅｒ ２）的抑制物與其應用方法
|
|
WO2008049923A1
(en)
|
2006-10-27 |
2008-05-02 |
Boehringer Ingelheim International Gmbh |
CRYSTALLINE FORM OF 4-(ß-D-GLUCOPYRANOS-1-YL)-1-METHYL-2-[4-((S)-TETRAHYDROFURAN-3-YLOXY)-BENZYL]-BENZENE, A METHOD FOR ITS PREPARATION AND THE USE THEREOF FOR PREPARING MEDICAMENTS
|
|
CA2668623A1
(en)
*
|
2006-11-06 |
2008-05-15 |
Boehringer Ingelheim International Gmbh |
Glucopyranosyl-substituted benzyl-benzonitrile derivatives, medicaments containing such compounds, their use and process for their manufacture
|
|
WO2008075736A1
(ja)
*
|
2006-12-21 |
2008-06-26 |
Astellas Pharma Inc. |
Ｃ－グリコシド誘導体の製造方法及びその合成中間体
|
|
US7795228B2
(en)
*
|
2006-12-28 |
2010-09-14 |
Theracos, Inc. |
Spiroheterocyclic glycosides and methods of use
|
|
WO2008101939A1
(en)
*
|
2007-02-21 |
2008-08-28 |
Boehringer Ingelheim International Gmbh |
Tetrasubstituted glucopyranosylated benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
|
|
US7846945B2
(en)
*
|
2007-03-08 |
2010-12-07 |
Lexicon Pharmaceuticals, Inc. |
Piperdine-based inhibitors of sodium glucose co-transporter 2 and methods of their use
|
|
CL2008002427A1
(es)
|
2007-08-16 |
2009-09-11 |
Boehringer Ingelheim Int |
Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2.
|
|
NZ583369A
(en)
|
2007-08-23 |
2011-08-26 |
Theracos Inc |
Benzylbenzene derivatives and methods of use
|
|
RS56990B1
(sr)
*
|
2007-09-10 |
2018-05-31 |
Janssen Pharmaceutica Nv |
Postupak za dobijanje jedinjenja koja su korisna kao inhibitori sglt
|
|
JP5498392B2
(ja)
*
|
2007-11-30 |
2014-05-21 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
１，５−ジヒドロ−ピラゾロ［３，４−ｄ］ピリミジン−４−オン誘導体及びｃｎｓ障害の治療のためのｐｄｅ９ａモジュレーターとしてのそれらの使用
|
|
UA101004C2
(en)
|
2007-12-13 |
2013-02-25 |
Теракос, Инк. |
Derivatives of benzylphenylcyclohexane and use thereof
|
|
ES2541141T3
(es)
*
|
2008-01-31 |
2015-07-16 |
Astellas Pharma Inc. |
Composición farmacéutica para el tratamiento de las enfermedades del hígado graso
|
|
UA105362C2
(en)
|
2008-04-02 |
2014-05-12 |
Бьорингер Ингельхайм Интернациональ Гмбх |
1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
|
|
US8791077B2
(en)
|
2008-05-22 |
2014-07-29 |
Astrazeneca Ab |
Method for treating hyperuricemia employing an SGLT2 inhibitor and composition containing same
|
|
AU2009270936B2
(en)
|
2008-07-15 |
2014-12-18 |
Theracos, Inc. |
Deuterated benzylbenzene derivatives and methods of use
|
|
CN103910702A
(zh)
|
2008-08-22 |
2014-07-09 |
泰拉科斯有限公司 |
制备sglt2抑制剂的方法
|
|
AU2009286380B2
(en)
*
|
2008-08-28 |
2011-09-15 |
Pfizer Inc. |
Dioxa-bicyclo[3.2.1.]octane-2,3,4-triol derivatives
|
|
KR20110063447A
(ko)
|
2008-09-08 |
2011-06-10 |
베링거 인겔하임 인터내셔날 게엠베하 |
피라졸로피리미딘 및 ｃｎｓ 장애의 치료를 위한 이들의 용도
|
|
US9056850B2
(en)
|
2008-10-17 |
2015-06-16 |
Janssen Pharmaceutica N.V. |
Process for the preparation of compounds useful as inhibitors of SGLT
|
|
US20110014284A1
(en)
|
2009-02-13 |
2011-01-20 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
|
|
DK2396005T3
(da)
|
2009-02-13 |
2026-02-09 |
Boehringer Ingelheim Int |
Sglt2 hæmmer til at forbedre glykæmisk kontrol
|
|
JP5685550B2
(ja)
|
2009-02-13 |
2015-03-18 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Ｓｇｌｔ２阻害剤、ｄｐｐ−ｉｖ阻害剤、更に必要により抗糖尿病薬を含む医薬組成物及びその使用
|
|
UY32427A
(es)
|
2009-02-13 |
2010-09-30 |
Boheringer Ingelheim Internat Gmbh |
Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma
|
|
PT2414363E
(pt)
|
2009-03-31 |
2014-02-26 |
Boehringer Ingelheim Int |
Derivados de 1-heterociclil-1,5-di-hidro-pirazolo[3,4- d]pirimidin-4-ona e sua utilização como moduladores de pde9a
|
|
US8541380B2
(en)
*
|
2009-06-19 |
2013-09-24 |
Green Cross Corporation |
C-aryl glucoside SGLT2 inhibitors and pharmaceutical compositions comprising same
|
|
US20110009347A1
(en)
|
2009-07-08 |
2011-01-13 |
Yin Liang |
Combination therapy for the treatment of diabetes
|
|
EP2451797B1
(en)
|
2009-07-10 |
2013-04-03 |
Janssen Pharmaceutica, N.V. |
CRYSTALLISATION PROCESS FOR 1-(ß-D-GLUCOPYRANOSYL)-4-METHYL-3-[5-(4-FLUOROPHENYL)-2-THIENYLMETHYL]BENZENE
|
|
TW201118099A
(en)
*
|
2009-08-12 |
2011-06-01 |
Boehringer Ingelheim Int |
New compounds for the treatment of CNS disorders
|
|
EA020798B1
(ru)
|
2009-09-30 |
2015-01-30 |
Бёрингер Ингельхайм Интернациональ Гмбх |
СПОСОБ ПОЛУЧЕНИЯ КРИСТАЛЛИЧЕСКОЙ ФОРМЫ 1-ХЛОР-4-(β-D-ГЛЮКОПИРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГИДРОФУРАН-3-ИЛОКСИ)БЕНЗИЛ]БЕНЗОЛА
|
|
PT2486029E
(pt)
|
2009-09-30 |
2015-10-14 |
Boehringer Ingelheim Int |
Processos para a preparação de derivados de benzil-benzeno substituídos com glucopiranosilo
|
|
UY32919A
(es)
|
2009-10-02 |
2011-04-29 |
Boehringer Ingelheim Int |
Composición farmacéutica, forma de dosificación farmacéutica, procedimiento para su preparación, mé todos para su tratamiento y sus usos
|
|
HUE031375T2
(en)
|
2009-10-14 |
2017-07-28 |
Janssen Pharmaceutica Nv |
Process for the preparation of compounds useful as inhibitors of sglt2
|
|
RS53827B1
(sr)
|
2009-11-02 |
2015-06-30 |
Pfizer Inc. |
Derivati dioksa-biciklo[3.2.1]oktan-2,3,4-triola
|
|
AR079438A1
(es)
|
2009-12-09 |
2012-01-25 |
Panacea Biotec Ltd |
Derivados de azucar, composiciones farmaceuticas y sus usos
|
|
EP2552442A1
(en)
|
2010-03-30 |
2013-02-06 |
Boehringer Ingelheim International GmbH |
Pharmaceutical composition comprising an sglt2 inhibitor and a ppar- gamma agonist and uses thereof
|
|
SG10201506114UA
(en)
|
2010-05-11 |
2015-09-29 |
Janssen Pharmaceutica Nv |
Pharmaceutical formulations comprising 1 - (beta-d-glucopyranosyl) - 2 -thienylmethylbenzene derivatives as inhibitors of sglt
|
|
WO2011153712A1
(en)
|
2010-06-12 |
2011-12-15 |
Theracos, Inc. |
Crystalline form of benzylbenzene sglt2 inhibitor
|
|
EP2603511B1
(en)
|
2010-08-12 |
2017-03-15 |
Boehringer Ingelheim International GmbH |
6-cycloalkyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a inhibitors
|
|
WO2012041898A1
(en)
|
2010-09-29 |
2012-04-05 |
Celon Pharma Sp. Z O.O. |
Combination of sglt2 inhibitor and a sugar compound for the treatment of diabetes
|
|
US20120283169A1
(en)
|
2010-11-08 |
2012-11-08 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
|
US20130035281A1
(en)
|
2011-02-09 |
2013-02-07 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
|
US8809345B2
(en)
|
2011-02-15 |
2014-08-19 |
Boehringer Ingelheim International Gmbh |
6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
|
|
WO2012109996A1
(zh)
*
|
2011-02-18 |
2012-08-23 |
上海璎黎科技有限公司 |
一种芳基糖苷类化合物及其制备方法和应用
|
|
AR085689A1
(es)
|
2011-03-07 |
2013-10-23 |
Boehringer Ingelheim Int |
Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2
|
|
EP2697218B1
(en)
|
2011-04-13 |
2016-05-25 |
Janssen Pharmaceutica NV |
Process for the preparation of compounds useful as inhibitors of sglt2
|
|
US8957033B2
(en)
*
|
2011-04-25 |
2015-02-17 |
Beijing Prelude Pharm. Sci. & Tech. Co., Ltd. |
Inhibitor of sodium-dependent glucose transport protein and preparation method therefor and use thereof
|
|
TWI542596B
(zh)
|
2011-05-09 |
2016-07-21 |
健生藥品公司 |
（２ｓ,３ｒ,４ｒ,５ｓ,６ｒ）－２－（３－（（５－（４－氟苯基）噻吩－２－基）甲基）－４－甲基苯基）－６－（羥甲基）四氫－２ｈ－哌喃－３,４,５－三醇之ｌ－脯胺酸及檸檬酸共晶體
|
|
BR112013031032A2
(pt)
|
2011-06-03 |
2016-11-29 |
Boehringer Ingelheim Int |
inibidores de sglt-2 para o tratamento de distúrbios metabólicos em pacientes tratados com agentes neurolépticos
|
|
US20130035298A1
(en)
|
2011-07-08 |
2013-02-07 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
|
US9018249B2
(en)
|
2011-09-13 |
2015-04-28 |
Panacea Biotec Limited |
SGLT inhibitors
|
|
KR102668696B1
(ko)
|
2012-01-12 |
2024-05-29 |
예일 유니버시티 |
E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법
|
|
US9555001B2
(en)
|
2012-03-07 |
2017-01-31 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition and uses thereof
|
|
US9192617B2
(en)
|
2012-03-20 |
2015-11-24 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
|
WO2013152476A1
(en)
|
2012-04-10 |
2013-10-17 |
Theracos, Inc. |
Process for the preparation of benzylbenzene sglt2 inhibitors
|
|
PT2981269T
(pt)
|
2013-04-04 |
2023-10-10 |
Boehringer Ingelheim Vetmedica Gmbh |
Tratamento de distúrbios metabólicos em animais equinos
|
|
TR201901110T4
(tr)
|
2013-04-05 |
2019-02-21 |
Boehringer Ingelheim Int |
Empagliflozinin terapötik kullanımları.
|
|
US11813275B2
(en)
|
2013-04-05 |
2023-11-14 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
|
CA2812519A1
(en)
|
2013-04-05 |
2014-10-05 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
|
HK1213818A1
(zh)
|
2013-04-05 |
2016-07-15 |
勃林格殷格翰国际有限公司 |
依帕列净的治疗用途
|
|
EP4678242A3
(en)
|
2013-04-18 |
2026-03-18 |
Boehringer Ingelheim International GmbH |
Pharmaceutical composition, methods for treating and uses thereof
|
|
GB201311888D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
|
GB201311891D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compound
|
|
ES2605886T3
(es)
|
2013-09-27 |
2017-03-16 |
Sunshine Lake Pharma Co., Ltd. |
Derivados de glucopiranosilo y sus usos en medicina
|
|
CN105611920B
(zh)
|
2013-10-12 |
2021-07-16 |
泰拉科斯萨普有限责任公司 |
羟基-二苯甲烷衍生物的制备
|
|
ES2969764T3
(es)
|
2013-12-17 |
2024-05-22 |
Boehringer Ingelheim Vetmedica Gmbh |
Un inhibidor de SGLT-2 para usar en el tratamiento de un trastorno metabólico en animales felinos
|
|
US9902751B2
(en)
|
2013-12-30 |
2018-02-27 |
Mylan Laboratories Limited |
Process for the preparation of empagliflozin
|
|
CN115671290A
(zh)
*
|
2014-01-23 |
2023-02-03 |
勃林格殷格翰动物保健有限公司 |
犬科动物中代谢紊乱的治疗
|
|
WO2015150299A2
(en)
|
2014-04-01 |
2015-10-08 |
Boehringer Ingelheim Vetmedica Gmbh |
Treatment of metabolic disorders in equine animals
|
|
US20180228907A1
(en)
|
2014-04-14 |
2018-08-16 |
Arvinas, Inc. |
Cereblon ligands and bifunctional compounds comprising the same
|
|
CN106536498A
(zh)
|
2014-06-24 |
2017-03-22 |
堪萨斯大学 |
作为hsp90抑制剂和hsp70诱导剂的具有经修饰醚基的联苯酰胺
|
|
US10071164B2
(en)
|
2014-08-11 |
2018-09-11 |
Yale University |
Estrogen-related receptor alpha based protac compounds and associated methods of use
|
|
WO2016046150A1
(en)
|
2014-09-25 |
2016-03-31 |
Boehringer Ingelheim Vetmedica Gmbh |
Combination treatment of sglt2 inhibitors and dopamine agonists for preventing metabolic disorders in equine animals
|
|
EA201791982A1
(ru)
|
2015-03-09 |
2020-02-17 |
Интекрин Терапьютикс, Инк. |
Способы лечения неалкогольной жировой болезни печени и/или липодистрофии
|
|
KR102659761B1
(ko)
|
2015-08-27 |
2024-04-24 |
베링거잉겔하임베트메디카게엠베하 |
Sglt-2 억제제를 포함하는 액상 약제학적 조성물
|
|
US20170071970A1
(en)
|
2015-09-15 |
2017-03-16 |
Janssen Pharmaceutica Nv |
Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
|
|
EP3362055B1
(en)
|
2015-10-15 |
2023-01-18 |
Boehringer Ingelheim International GmbH |
Sglt-2 inhibitor for use in the treatment of a metabolic myopathy
|
|
BR112018008918A8
(pt)
|
2015-11-02 |
2019-02-26 |
Univ Yale |
compostos de quimera proteólise dirigida e métodos para preparação e uso dos mesmos
|
|
WO2017141202A1
(en)
|
2016-02-17 |
2017-08-24 |
Lupin Limited |
Complex of sglt2 inhibitor and process for preparation thereof
|
|
KR20190084096A
(ko)
|
2016-11-10 |
2019-07-15 |
베링거 인겔하임 인터내셔날 게엠베하 |
약제학적 조성물, 치료 방법 및 이의 용도
|
|
JP2020515639A
(ja)
|
2017-04-03 |
2020-05-28 |
コヒラス・バイオサイエンシズ・インコーポレイテッド |
進行性核上性麻痺の処置のためのＰＰＡＲγアゴニスト
|
|
KR102204439B1
(ko)
|
2018-05-14 |
2021-01-18 |
에이치케이이노엔 주식회사 |
Sglt-2 억제제 및 dpp-iv 억제제를 포함하는 약제학적 조성물
|
|
KR20210021457A
(ko)
|
2018-05-14 |
2021-02-26 |
리아타 파마슈티컬즈, 아이엔씨. |
열충격 단백질 경로와 연관된 질환의 치료를 위한 변형된 당기를 가진 바이아릴 아마이드
|
|
WO2020039394A1
(en)
|
2018-08-24 |
2020-02-27 |
Novartis Ag |
New drug combinations
|
|
EP3957634A4
(en)
*
|
2019-07-05 |
2022-08-31 |
Shangdong Danhong Pharmaceutical Co., Ltd. |
SGLT INHIBITOR IN CRYSTAL FORM AND ITS USE
|
|
US12378277B2
(en)
*
|
2019-07-26 |
2025-08-05 |
Dongbao Purple Star (Hangzhou) Biopharmaceutical Co., Ltd. |
SGLTS/DPP4 inhibitor and application thereof
|
|
EP4064854A1
(en)
|
2019-11-28 |
2022-10-05 |
Boehringer Ingelheim Vetmedica GmbH |
Use of sglt-2 inhibitors in the drying-off of non-human mammals
|
|
AU2021222297B2
(en)
|
2020-02-17 |
2026-01-22 |
Boehringer Ingelheim Vetmedica Gmbh |
Use of SGLT-2 inhibitors for the prevention and/or treatment of cardiac diseases in felines
|
|
IL296035A
(en)
|
2020-03-06 |
2022-10-01 |
Vertex Pharma |
Methods of treating apol-1 dependent focal segmental glomerulosclerosis
|
|
WO2022051316A1
(en)
|
2020-09-03 |
2022-03-10 |
Coherus Biosciences, Inc. |
Fixed dose combinations of chs-131 and a sglt-2 inhibitor
|
|
JP2024527434A
(ja)
|
2021-07-28 |
2024-07-24 |
ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー |
ネコ科動物を除く非ヒト哺乳動物、特にイヌ科動物における心臓疾患の予防及び／又は治療のためのｓｇｌｔ－２阻害剤の使用
|
|
JP2024525981A
(ja)
|
2021-07-28 |
2024-07-12 |
ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー |
ヒト以外の哺乳動物における腎疾患の予防及び／又は治療のためのｓｇｌｔ－２阻害剤の使用
|
|
AU2023277704A1
(en)
|
2022-05-25 |
2024-12-05 |
Boehringer Ingelheim Vetmedica Gmbh |
Aqueous pharmaceutical compositions comprising sglt-2 inhibitors
|
|
EP4676494A1
(en)
|
2023-03-06 |
2026-01-14 |
Boehringer Ingelheim Vetmedica GmbH |
Systems for delivery of liquid pharmaceutical compositions in particular comprising one or more sglt-2 inhibitor(s)
|
|
US20240390317A1
(en)
|
2023-05-24 |
2024-11-28 |
Boehringer Ingelheim Vetmedica Gmbh |
Combination treatment and/or prevention of cardiac diseases in non-human mammals comprising one or more sglt-2 inhibitors and pimobendan and/or telmisartan
|
|
KR20260019532A
(ko)
|
2023-05-24 |
2026-02-10 |
베링거잉겔하임베트메디카게엠베하 |
하나 이상의 sglt-2 억제제와 텔미사르탄을 포함하는 비인간 포유류의 신장 질환 및/또는 고혈압의 병용 치료 및/또는 예방
|